These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9433653)

  • 1. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
    Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
    Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of age and gender on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of grepafloxacin.
    Efthymiopoulos C
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A; Gambertoglio JG
    Clin Pharmacokinet; 1997; 33 Suppl 1():32-8. PubMed ID: 9433654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theophylline and warfarin interaction studies with grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A; Blum B
    Clin Pharmacokinet; 1997; 33 Suppl 1():39-46. PubMed ID: 9433655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food and gastric pH on the bioavailability of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():18-24. PubMed ID: 9433652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
    Kozawa O; Uematsu T; Matsuno H; Niwa M; Nagashima S; Kanamaru M
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2824-8. PubMed ID: 9124849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
    Child J; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.
    McCormack WM; Martin DH; Hook EW; Jones RB
    Infect Dis Obstet Gynecol; 1998; 6(3):109-15. PubMed ID: 9785106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
    Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits.
    Perez S; Solans C; Bregante MA; Pinilla I; García MA; Honrubia F
    J Antimicrob Chemother; 2002 Oct; 50(4):541-5. PubMed ID: 12356799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
    Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat.
    Sasabe H; Kato Y; Terasaki T; Tsuji A; Sugiyama Y
    Biopharm Drug Dispos; 1999 Apr; 20(3):151-8. PubMed ID: 10211868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
    J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.